Innovair

Formoterol fumarate, the active ingredient in Innovair, is a combination inhaled corticosteroid/long‑acting β2‑agonist presented as a metered dose inhaler for inhalation use. It treats asthma and chronic obstructive pulmonary disease as maintenance therapy in adults and children.

GNH USA supplies Innovair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innovair is a combination inhaled corticosteroid/long‑acting β2‑agonist indicated for maintenance therapy in airway diseases.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): maintains lung function, decreases breathlessness and lowers exacerbation risk. - Exercise‑induced bronchoconstriction (as part of asthma management): provides sustained bronchodilation to prevent exercise‑related airway narrowing.

Adverse reactions may occur with any inhaled therapy. Patients should be aware of both frequent and less common events.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth. - Hoarseness or dysphonia: voice changes after inhalation. - Throat irritation or dry mouth. - Cough or wheeze immediately after use. - Headache. - Tremor.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: especially in COPD patients. - Cardiac arrhythmias or tachycardia. - Severe allergic reactions: rash, swelling, anaphylaxis. - Hyperglycaemia: elevated blood glucose levels.

Before prescribing Innovair, clinicians should consider several safety aspects.

- Monitor for oral candidiasis: advise rinsing mouth after each inhalation. - Assess adrenal function: especially with high‑dose or prolonged use. - Use cautiously in patients with cardiovascular disease: monitor heart rate and blood pressure. - Avoid abrupt discontinuation: taper to prevent loss of asthma control. - Store at room temperature: keep inhaler in original packaging, protect from moisture and heat.

Innovair may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator response. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can raise corticosteroid exposure. - Monoamine oxidase inhibitors (MAOIs): may enhance sympathomimetic effects of formoterol. - Diuretics: increase risk of hypokalaemia when combined with β2‑agonists.

Moderate Interactions (Monitor Closely): - Concomitant inhaled corticosteroids: risk of systemic glucocorticoid effects. - Other LABA or sympathomimetic agents: additive cardiovascular stimulation. - Ritonavir or other strong CYP3A4 inhibitors: may elevate formoterol plasma levels.